Compare EHAB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHAB | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.5M | 417.1M |
| IPO Year | N/A | N/A |
| Metric | EHAB | PROK |
|---|---|---|
| Price | $9.53 | $2.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.00 | $6.25 |
| AVG Volume (30 Days) | 606.8K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,047,800,000.00 | $744,000.00 |
| Revenue This Year | $4.95 | $918.66 |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $6.47 | $0.46 |
| 52 Week High | $10.91 | $7.13 |
| Indicator | EHAB | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 70.29 | 41.28 |
| Support Level | $7.87 | $2.04 |
| Resistance Level | $8.39 | $2.25 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 90.31 | 26.19 |
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.